CAR T-cell therapy Market with COVID-19 Impact Analysis, By Drug Type (Axicabtagene, Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), By Indication (Lymphoma, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Others), By End User (Hospitals, Cancer Treatment Centers), By Country, and By Region Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
CAR T-cell therapy Market size was valued at USD 2,308.4 million in 2022, expanding at a CAGR of 21.8% from 2023 to 2030.
Chimeric antigen receptor (CAR)-T cell therapy has been revolutionary as it has produced remarkably effective and durable clinical responses. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy. These therapies do not require aggressive chemotherapy, and unless there is an elevation in cytokines following infusion, patients receiving CAR T-cells do not typically require immunosuppression. The advantage of chimeric antigen receptor (CAR) T-cell therapy is that it is administered in a single infusion, requiring a shorter treatment time. Also, It Improves immunogenic memory, which provides continuous surveillance to treat local and distant metastatic lesions. The main benefit of CAR-T therapy is that it can be curative for people whose blood cancer has not responded to other types of treatments. While CAR-T therapy is often considered a last resort, it is often an effective one.
CAR T-cell therapy Market- Market Dynamics
The increasing prevalence of cancer is expected to propel market demand
The increasing prevalence of cancer is expected to dominate the growth of the CAR T-cell therapy Market. Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. Currently, available CAR T-cell therapies are customized for each individual patient. According to World health organization, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In the United States alone, well over 1000 patients have now received CAR-T cells, and several studies have opened looking at the long-term effects in responders. Advancing research on novel biotherapies and increasing the supply and safety of biologics are the factors that are expected to provide growth opportunities for the CAR T-cell therapy market. The severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration are the factors which restrict the growth of market.
CAR T-cell Therapy Market- Key Insights
- As per the analysis shared by our research analyst, the global paper bags packaging market is estimated to grow annually at a CAGR of around 21.8% over the forecast period (2023-2030)
- The paper bags packaging industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
- Based on Drug Type segmentation, Tisagenlecleucel drug type was predicted to show maximum market share in the year 2022
- Based on Indication segmentation, Lymphoma was the leading type in 2022
- Based on End-User segmentation, Hospitals was the leading type in 2022
- On the basis of region, North America was the leading revenue generator in 2022
CAR T-cell Therapy Market- Segmentation Analysis:
The Global CAR T-cell therapy Market is segmented on the basis of Drug Type, Indication, End User, and Region.
The market is divided into five categories based on Drug Type: Ciloleucel, Tisagenlecleucel, Axicabtagene, Autoleucel, Brexucabtagene, and Others. Tisagenlecleucel drug type dominates the market. One such recently licensed product has been Tisagenlecleucel, a CAR T therapy approved for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) using autologous T cells from the patient. Since Tisagenlecleucel is now a standard of care treatment for B-ALL, it is clinically essential to be able to accurately monitor these CAR T cells in patients.
The market is divided into six categories based on Indication: Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Lymphoma, Acute Lymphocytic Leukemia, and Others. dominates the market and is likely to maintain its dominance during the forecast period. It is a highly specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer.
The market is divided into six categories based on End –User: Hospitals and Cancer Treatment Centers. Hospitals are the leading type in 2022. Hospitals with specialized cancer centers or designated CAR T-cell therapy programs are equipped to handle the administration of this therapy. They have the infrastructure, facilities and experienced health professionals to provide safe and effective treatment.
CAR T-cell therapy Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The increasing burden of cancer and the rise in research and development to develop CAR T-cell therapy is expected to drive the growth of CAR T-cell therapy Market in north America. According to the American cancer society, number of new cancer cases and deaths in 2021 (In 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. Europe and Asia Pacific are expected to propel significant growth in CAR T-cell therapy Market, due to the Growing Product Approvals Associated with Chimeric antigen receptor (CAR)-T cell therapy.
CAR T-cell therapy Market- Competitive Landscape:
Companies invest heavily in research and development to enhance their cell line development technologies, develop new products, and explore novel therapeutic applications. These players offer a wide range of services, including contract research, contract manufacturing, clinical trial services, and other support services for biopharmaceutical companies. A biotech company developing a platform technology to improve the safety of CAR T-cell therapies asked Alacrity to conduct a comprehensive competitive landscape to better understand the current CAR T-cell therapy space. The company wanted to understand the product profiles of top CAR T-cell therapies in development, current challenges in the field and solutions other companies are employing, as well as the deals landscape. This would help guide their business and product development strategy to maximize the value of their technology.
Recent Developments:
- In May 2, 2023 –one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced nowadays that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.
Key features of the study:
- This proposed research study on CAR T-cell therapy market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
- The report provides the client the latest up-to-date and trending insights about the CAR T-cell therapy market.
- The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for CAR T-cell therapy market
- The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the CAR T-cell therapy market
- Impact of COVID-19 on CAR T-cell therapy market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on CAR T-cell therapy market post-COVID will also be covered.
- In order to give the users of this report a comprehensive view on the CAR T-cell therapy market, we have also included competitive landscape and key innovator analysis for the CAR T-cell therapy market.
- The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
- The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the CAR T-cell therapy market.
- In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
- The global CAR T-cell therapy market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CAR T-CELL THERAPY MARKET KEY PLAYERS
- Johnson & Johnson Services, Inc.
- ALLOGENE THERAPEUTICS
- Lonza
- Aurora Biopharma
- Cartesian Therapeutics, Inc.
- Novartis
- Bristol-Myers Squibb company
- Gilead Sciences
- Curocell Inc
- JW Therapeutics
GLOBAL CAR T-CELL THERAPY MARKET, BY DRUG TYPE
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION
- Lymphoma
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia (CLL)
- Multiple Myeloma (MM)
- Others
GLOBAL CAR T-CELL THERAPY MARKET, BY END-USER
- Hospitals
- Cancer Treatment Centers
GLOBAL CAR T-CELL THERAPY MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. CAR T-Cell Therapy Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. CAR T-Cell Therapy Market Snippet by Drug Type
2.1.2. CAR T-Cell Therapy Market Snippet by Indication
2.1.3. CAR T-Cell Therapy Market Snippet by End User
2.1.4. CAR T-Cell Therapy Market Snippet by Country
2.1.5. CAR T-Cell Therapy Market Snippet by Region
2.2. Competitive Insights
3. CAR T-Cell Therapy Key Market Trends
3.1. CAR T-Cell Therapy Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. CAR T-Cell Therapy Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. CAR T-Cell Therapy Market Opportunities
3.4. CAR T-Cell Therapy Market Future Trends
4. CAR T-Cell Therapy Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. CAR T-Cell Therapy Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. CAR T-Cell Therapy Market Landscape
6.1. CAR T-Cell Therapy Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. CAR T-Cell Therapy Market – By Drug Type
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Type, 2022 & 2030 (%)
7.1.2. Axicabtagene Ciloleucel
7.1.3. Tisagenlecleucel
7.1.4. Brexucabtagene Autoleucel
7.1.5. Others
8. CAR T-Cell Therapy Market – By Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
8.1.2. Lymphoma
8.1.3. Acute Lymphocytic Leukemia
8.1.4. Chronic Lymphocytic Leukemia (CLL)
8.1.5. Multiple Myeloma (MM)
8.1.6. Others
9. CAR T-Cell Therapy Market – By End User
9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
9.1.2. Hospitals
9.1.3. Cancer Treatment Centers
10. CAR T-Cell Therapy Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
10.2. North America
10.2.1. Overview
10.2.2. CAR T-Cell Therapy Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.2.5. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.2.6. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. CAR T-Cell Therapy Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.10.5. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. CAR T-Cell Therapy Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.7.5. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.8.5. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. CAR T-Cell Therapy Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. CAR T-Cell Therapy Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11. Key Vendor Analysis- CAR T-Cell Therapy Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Johnson & Johnson Services, Inc.
11.2.2. ALLOGENE THERAPEUTICS
11.2.3. Lonza
11.2.4. Aurora Biopharma
11.2.5. Cartesian Therapeutics, Inc.
11.2.6. Novartis
11.2.7. Bristol-Myers Squibb company
11.2.8. Gilead Sciences
11.2.9. Curocell Inc
11.2.10. JW Therapeutics
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
